Valuation: NetraMark Holdings Inc.

Market Cap 76.98M 54.14M 47.42M 43.67M 40.54M 5.16B 78.02M 523M 203M 2.53B 203M 199M 8.79B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 76.98M 54.14M 47.42M 43.67M 40.54M 5.16B 78.02M 523M 203M 2.53B 203M 199M 8.79B EV / Sales 2026 *
192x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
1 day-2.41%
1 week+28.57%
Current month+28.57%
1 month-5.81%
3 months-3.57%
6 months-20.59%
Current year-26.36%
1 week 0.6
Extreme 0.6
0.83
1 month 0.59
Extreme 0.59
0.88
Current year 0.59
Extreme 0.59
1.28
1 year 0.59
Extreme 0.59
1.8
3 years 0.16
Extreme 0.155
1.8
5 years 0.15
Extreme 0.15
2.39
10 years 0.15
Extreme 0.15
3.17
Manager TitleAgeSince
Chief Executive Officer - 2022-02-16
President - 2022-07-03
Director of Finance/CFO 57 2022-07-17
Director TitleAgeSince
Chairman 40 2025-06-08
Director/Board Member - -
Director/Board Member - 2022-06-15
Date Insider Type Main position Quantity % Market Cap.
Apr. 13Sell

Chief Technology Officer

14,286 0.0154%
Apr. 12Tax

Chairperson

434,178 0.4686%
Apr. 08Tax

Chairperson

434,208 0.4687%
Change 5-day change 1-year change 3-year change Capi.($)
-2.41%+28.57%-37.69%+194.55% 54.14M
+1.88%+5.35%-21.05%+16.53% 2,873B
+2.17%+16.38%-2.40%+785.12% 318B
+1.33%-6.34%+277.76%+899.96% 127B
-1.68%-1.69%+15.20%+62.63% 104B
+3.37%+1.82%+73.94%+170.46% 90.9B
-2.13%-3.05%-19.40%+0.27% 84.69B
-0.38%+9.61%-30.49%+91.05% 64.31B
+0.46%+3.49%+6.67%+80.68% 47.98B
-0.32%+4.63%-47.20%+38.27% 40.83B
Average +0.25%+7.45%+21.53%+233.95% 374.97B
Weighted average by Cap. +1.60%+5.23%-6.12%+118.48%

Financials

2026 *2027 *
Net sales 401K 282K 247K 227K 211K 26.9M 406K 2.72M 1.06M 13.2M 1.06M 1.04M 45.78M -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-
Date Price Change Volume
26-07-07 CA$0.8100 -2.41% 19,000
26-07-06 CA$0.8300 +3.75% 22,003
26-07-03 CA$0.8000 +6.67% 39,002
26-07-02 CA$0.7500 +19.05% 140,303
26-06-30 CA$0.6300 +1.61% 140,002

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AIAI Stock